Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 25, Issue 8, 2009, Pages 508-513

  Zacchè, Martino M ^a   Caputo, Luigi ^a   Filippis, Susanna ^a   Zacchè, Gabrio ^b   Dindelli, Moreno ^a   Ferrari, Augusto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Cutaneous disorders; Hyperandrogenism; Hyperinsulinemia; Myo inositol; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; FOLIC ACID; FOLLITROPIN; INOFOLIC; INOSITOL; INSULIN; LUTEINIZING HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ACNE; ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; METABOLISM; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ACNE VULGARIS; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIRSUTISM; HOMEOSTASIS; HUMANS; INOSITOL; INSULIN; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TREATMENT OUTCOME; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 70350633732     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590903015544     Document Type: Article

References (43)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47. Review.
4. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-522.
5. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325-340.
6. Catrall FR, Healy DL. Long term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2004;18:803-812.
7. Falsetti L, Gambera A, Andrico S, Sartori F. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrinemetabolic and ultrasonographic differences. Gynaecol Endocrinol 2002;16:274-284.
8. Hatch R, Rosenfield RM, Kim MH, Tredway D. Hirsutism: implications, etiology and management. Am J Obstet Gynecol 1981;140:815-830.
9. Essah PA, Wickham EP III, Nunley JR, Nestler JE. Dermatology of androgen-related disorDers. Clin Dermatol 2006;24:289-298.
10. Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006;91:22-24.
11. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
12. Adashi EY, Resnick CE, D'Ercole AJ, Svoboda ME, Van Wyk JJ. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocrinol Rev 1985;6:400-420.
13. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904-910.
14. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-89.
15. Farshchi H, Rane A, Love A, Kennedy RL. Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. J Obstet Gynaecol 2007;27:762-773.
16. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz MJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002;77:209-215.
17. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic uses in non-insulin dependent diabetes. Drugs 1995;49:721-749.
18. Saltiel AR. Second messengers of insulin action. Diabetes care 1990;13:244-256.
19. Romero G, Larner J. Insulin mediators and the mechanism of insulin action. Adv Pharmacol 1993;24:21-50.
20. Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993;90:5924-5928.
21. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242-249.
22. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro-inositol urinary clearance in women with the polycystic ovary syndrome. Diabetes Care 2006b;29:300-305. (Pubitemid 44106508)
23. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Eng J Med 1999;340:1314-1320.
24. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrinol Pract 2002;8:417-423.
25. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151-159.
26. Yoshida K, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigation drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Endocrinol Pract 2006;72:1310-1315.
27. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myoinositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol Endocrinol 2007; 23:700-703.
28. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-144.
29. Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17:579-582.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher BF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function froma fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-419.
31. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM, Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1105-1120.
32. Shapiro J. Clinical practice. Hair loss in women. N Engl JMed 2007;357:1620-1630. [Comment in: N Engl J Med 2008;358: 533;author reply 533].
33. Rosenfield RL. Polycystic ovary syndrome and insulinresistant hyperinsulinemia. J Am Acad Dermatol 2001;45: S095-S104.
34. Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 2008, in press.
35. Futterweit W, Ryan GL. A patient's guide to PCOS. New York: Henry Holt; 2006.
36. Van Vloten WA, Van Halesen CW, Van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15.
37. Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril. 2008, in press.
38. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome. A position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007;92:4546-4556.
39. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47-54.
40. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br Med J 2003;327:951-957.
41. Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocrinol Pract 2005;11:126-134.
42. Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, Nestler JE. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390-1397.
43. Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008;23:1439-1446.